Subtype
Exocrine Pancreas Carcinoma
CI-CAN-00005225Explore in graph →
358 active trials5 approved drugs26 evidence items
- NCIt
- C3850
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005225Explore in graph →
Clinical trials
919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (136)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03611556 | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | completed | Phase 1 / Phase 2 | 213 | MedImmune LLCINDUSTRY | 4 | Oct 3, 2023 | clinicaltrials |
| NCT02427841 | Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT01726582 | Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") | completed | Phase 2 | 229 | Medical College of WisconsinOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT02324543 | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02047513 | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer(NEONAX) | completed | Phase 2 | 127 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02042378 | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | completed | Phase 2 | 19 | pharmaand GmbHINDUSTRY | 2 | Jun 13, 2023 | clinicaltrials |
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02806687 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer(THERGAP-02) | completed | Phase 2 | 68 | University Hospital, ToulouseOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 30 | Catalysis SLINDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT01547260 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer(LENAGEM) | completed | Phase 1 / Phase 2 | 34 | Maria LiljeforsOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02178709 | A Phase II Study of Neoadjuvant FOLFIRINOX | completed | Phase 2 | 48 | Indiana UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02125136 | Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer(NEOLAP) | completed | Phase 2 | 168 | AIO-Studien-gGmbHOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01660711 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | completed | Phase 2 | 22 | Endeavor HealthOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03410914 | Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy(PATCH-DP) | completed | Phase 2 | 52 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT01666730 | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT00031694 | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2021 | clinicaltrials |
| NCT02562898 | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 18 | Margaret TemperoOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT00026104 | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00114179 | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00769483 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01222689 | Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01896869 | FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer | completed | Phase 2 | 83 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT02749136 | Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | completed | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02981342 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 8 | Nov 20, 2019 | clinicaltrials |
| NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 1 / Phase 2 | 23 | AstraZenecaINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
| NCT00735917 | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | Apr 2, 2019 | clinicaltrials |
| NCT01233375 | Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | completed | Phase 2 | 19 | Clovis Oncology, Inc.INDUSTRY | 1 | Mar 11, 2019 | clinicaltrials |
| NCT02440958 | Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial | completed | Phase 2 | 50 | Yonsei UniversityOTHER | 0 | Feb 18, 2019 | clinicaltrials |
| NCT02005419 | Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | completed | Phase 2 | 300 | Xian-Jun YuOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02023021 | Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | completed | Phase 2 | 80 | Xian-Jun YuOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02558894 | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 2 | 65 | AstraZenecaINDUSTRY | 6 | Aug 2, 2018 | clinicaltrials |
| NCT01389440 | Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer(GEMCAD1003) | completed | Phase 2 | 24 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01234935 | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | completed | Phase 2 | 8 | Translational Oncology Research InternationalOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00383760 | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT00609336 | Perioperative Therapy for Resectable Pancreatic Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01016483 | Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 141 | EMD SeronoINDUSTRY | 2 | Jul 13, 2017 | clinicaltrials |
| NCT02117258 | Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma(ZIPANG) | completed | Phase 2 | 167 | Zeria PharmaceuticalINDUSTRY | 3 | Jul 2, 2017 | clinicaltrials |
| NCT00366457 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01369420 | NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 10 | Angiodynamics, Inc.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT01658943 | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy(S1115) | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
| NCT00474812 | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00998322 | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 34 | Oncolytics BiotechINDUSTRY | 1 | Apr 10, 2015 | clinicaltrials |
| NCT01232829 | Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2014 | clinicaltrials |
| NCT00577889 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00331682 | Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Oct 3, 2023source: clinicaltrials